Compare Summit Therapeutics Inc (SMMT) vs Xylem, Inc. (XYL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs Xylem, Inc. — how do they compare? Summit Therapeutics Inc trades at $14.57 (market cap $10.48B), while Xylem, Inc. trades at $120.79 (market cap $28.67B). The key difference: Xylem, Inc. is far larger — about 2.7× Summit Therapeutics Inc's market cap, and Xylem, Inc. pays a 1.43% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| SMMT | XYL | |
|---|---|---|
Market Cap | $10.48B | $28.67B |
Sector | Health | Industrials |
52-Week High | $29.32 | $152.95 |
52-Week Low | $13.05 | $106.34 |
Enterprise Value | $9.90B | $29.92B |
Dividend Yield | — | 1.43% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About Xylem, Inc.
Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $6.2 billion in revenue and $611 million in adjusted operating income in 2021.
Read more on XYL →
